{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04851301",
            "orgStudyIdInfo": {
                "id": "HP-00095888"
            },
            "organization": {
                "fullName": "University of Maryland, Baltimore",
                "class": "OTHER"
            },
            "briefTitle": "Neural Mechanisms of Immersive Virtual Reality in Chronic Pain",
            "officialTitle": "Neural Mechanisms of Immersive Virtual Reality in Chronic Pain",
            "therapeuticArea": [
                "Other"
            ],
            "study": "neural-mechanisms-of-immersive-virtual-reality-in-chronic-pain"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-11-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-10-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-04-06",
            "studyFirstSubmitQcDate": "2021-04-14",
            "studyFirstPostDateStruct": {
                "date": "2021-04-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Luana Colloca",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Maryland, Baltimore"
            },
            "leadSponsor": {
                "name": "University of Maryland, Baltimore",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This project examines, in chronic pain, the mechanisms of immersive virtual reality compared to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological premises for low-risk interventions for pain management is high.",
            "detailedDescription": "Virtual reality (VR) has been seen as an intervention for alleviating clinical chronic (and acute) pain. An approach to pain management utilizing VR presents opportunities for reducing pain and suffering by using immersive, aesthetic, and multisensory stimulation. Investigator will analyze the behavioral and neural mechanisms of active VR against sham VR as two methods that investigate descending pain modulation. Thus, the central hypothesis is that those who respond to placebos will likely respond to active VR. If VR-induced analgesia depends upon the release of endogenous opioids.\n\nIn this project, the investigators will determine the effects of VR at the neural and clinical levels directly for TMD participants, inviting participants from an existing Colloca Lab-based cohort phenotyped for diagnosis, grade, and low/high impact pain profiles and prospective TMD participants in collaboration with Johns Hopkins University. These participants have agreed to be recontacted for further research. Investigator will determine the role of the opioid tone (AIM1). In Aim 1, the investigators will determine the role of the endogenous opioid tone for VR-induced hypoalgesia in TMD participants using VR, tonic painful stimuli, and naloxone given intranasally with established mu-opioid receptor occupancy to determine how the opioid tone shapes VR-induced hypoalgesia."
        },
        "conditionsModule": {
            "conditions": [
                "Pain",
                "Virtual Reality",
                "Placebo",
                "Temporomandibular Disorder"
            ],
            "keywords": [
                "Naloxone",
                "Observation",
                "TMD volunteers",
                "VR"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "AIM 1: This is a double-blinded, randomized, between- and within-subjects design (3 X 3) with TMD participants randomly assigned to one of three groups. The three groups are 1. Naloxone group 2. Saline group 3. Natural history group, in which participants will not be given any drugs. Within-subjects factor: All three groups will go through the following 3 conditions:1. Active VR (theBlu); 2. Sham VR; 3. No-VR.",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "maskingDescription": "The UM Pharmacy will assign de-identified study IDs to participants and provide the study drug (Naloxone or Saline) so that participants, the person conducting the experiment, and the investigator will be blind to the participant's group.",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 259,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Naloxone",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "NARCAN\u00ae Naloxone Nasal Spray will be used to determine how the opioid tone shapes VR-induced hypoalgesia. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.",
                    "interventionNames": [
                        "Behavioral: Active Virtual Reality",
                        "Behavioral: sham Virtual Reality",
                        "Other: No Intervention",
                        "Drug: Naloxone"
                    ]
                },
                {
                    "label": "Saline",
                    "type": "SHAM_COMPARATOR",
                    "description": "Saline group, where participants will be given saline solution (4mg) via an identical spray device. Participants will be stratified for sex and then randomized to saline arm (The dose of saline will be (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.",
                    "interventionNames": [
                        "Behavioral: Active Virtual Reality",
                        "Behavioral: sham Virtual Reality",
                        "Other: No Intervention",
                        "Other: Saline"
                    ]
                },
                {
                    "label": "Natural History",
                    "type": "OTHER",
                    "description": "Natural history group, where participants will not be given any drugs. Participants will be stratified for sex and then randomized to the Natural History group.",
                    "interventionNames": [
                        "Behavioral: Active Virtual Reality",
                        "Behavioral: sham Virtual Reality",
                        "Other: No Intervention",
                        "Other: Natural history"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "Active Virtual Reality",
                    "description": "Participants will be assigned to an immersive VR environment.",
                    "armGroupLabels": [
                        "Naloxone",
                        "Natural History",
                        "Saline"
                    ],
                    "otherNames": [
                        "Active VR"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "sham Virtual Reality",
                    "description": "Participants will be assigned to a sham VR environment without the immersive experience.",
                    "armGroupLabels": [
                        "Naloxone",
                        "Natural History",
                        "Saline"
                    ],
                    "otherNames": [
                        "Sham VR"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "No Intervention",
                    "description": "Participants will experience tonic pain tolerance tests without exposure to any environments.",
                    "armGroupLabels": [
                        "Naloxone",
                        "Natural History",
                        "Saline"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Naloxone",
                    "description": "4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).\n\nA random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment.",
                    "armGroupLabels": [
                        "Naloxone"
                    ],
                    "otherNames": [
                        "Naloxone Hydrochloride/Narcan Intranasal"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Saline",
                    "description": "Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.\n\nA random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment.",
                    "armGroupLabels": [
                        "Saline"
                    ],
                    "otherNames": [
                        "Placebo, Sodium chloride"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Natural history",
                    "description": "Participants will not be provided Naloxone or Saline.",
                    "armGroupLabels": [
                        "Natural History"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Ischemic pain endurance",
                    "description": "Increments in experimental ischemic pain endurance will be assessed using a timer (minutes of tolerance)",
                    "timeFrame": "one session lasting from 2 to 3 hours"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Ischemic pain rating",
                    "description": "Increments in experimental ischemic pain endurance will be assessed using Visual Analogue Scale (VAS) (self-reported numbers) anchored from 0=no pain to 100=maximum tolerable pain. The VAS will be used every 10 seconds during the ischemic pain endurance task",
                    "timeFrame": "one session lasting from 2 to 3 hours"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age (18-88 years)\n* English speaker (written and spoken)\n* Temporal Mandibular Disorder (TMD) for at least 3 months\n\nExclusion Criteria:\n\n* Present or past degenerative neuromuscular disease\n* Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years\n* Cervical pain other than TMD related (e.g. stenosis, radiculopathy)\n* Any personal (or family first degree) history of mania, schizophrenia, or other psychoses\n* Severe psychiatric condition (e.g., schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.\n* Use of antidepressants, ADHD medication, non-over-the-counter painkillers, methadone, benzodiazepines, barbiturates, and/or narcotics during the past 3 months\n* Lifetime alcohol/drug dependence or alcohol/drug abuse in the past 3 months\n* Pregnancy or breastfeeding\n* Color-blindness\n* Pain in jaw or temple in last 3 months due to toothache or infection\n* Any facial trauma that has occurred in the last 6 weeks\n* History of severe facial trauma in the last 3 months\n* Impaired or uncorrected hearing\n* Conditions that would interfere with the VR mask placement (e.g. trauma, burn, infection)\n* Known history of severe motion sickness\n* High blood pressure or symptomatic low blood pressure\n* History of fainting\n* History of angioedema\n* Failed drug test (testing for opiates, cocaine, methamphetamines, amphetamines, and THC)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "88 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Research Coordinator",
                    "role": "CONTACT",
                    "phone": "410-706-5975",
                    "email": "NRSCollocaLab@umaryland.edu"
                },
                {
                    "name": "Rachel Massalee, MS",
                    "role": "CONTACT",
                    "email": "rmassalee@umaryland.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Luana Colloca, MD/PhD/MS",
                    "affiliation": "University of Maryland Baltimore School of Nursing",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Luana Colloca",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21201-1512",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Luana Colloca, MD,PhD,MS",
                            "role": "CONTACT",
                            "phone": "301-364-8089",
                            "email": "Colloca@umaryland.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "30817437",
                    "type": "BACKGROUND",
                    "citation": "Honzel E, Murthi S, Brawn-Cinani B, Colloca G, Kier C, Varshney A, Colloca L. Virtual reality, music, and pain: developing the premise for an interdisciplinary approach to pain management. Pain. 2019 Sep;160(9):1909-1919. doi: 10.1097/j.pain.0000000000001539. No abstract available."
                },
                {
                    "pmid": "32345915",
                    "type": "BACKGROUND",
                    "citation": "Colloca L, Raghuraman N, Wang Y, Akintola T, Brawn-Cinani B, Colloca G, Kier C, Varshney A, Murthi S. Virtual reality: physiological and behavioral mechanisms to increase individual pain tolerance limits. Pain. 2020 Sep 1;161(9):2010-2021. doi: 10.1097/j.pain.0000000000001900."
                },
                {
                    "pmid": "30216744",
                    "type": "BACKGROUND",
                    "citation": "Colloca L. The Placebo Effect in Pain Therapies. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:191-211. doi: 10.1146/annurev-pharmtox-010818-021542. Epub 2018 Sep 14."
                },
                {
                    "pmid": "9870976",
                    "type": "BACKGROUND",
                    "citation": "Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999 Jan 1;19(1):484-94. doi: 10.1523/JNEUROSCI.19-01-00484.1999."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "At this time, there is neither intent nor plan to share IPD."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013705",
                    "term": "Temporomandibular Joint Disorders"
                },
                {
                    "id": "D000013706",
                    "term": "Temporomandibular Joint Dysfunction Syndrome"
                },
                {
                    "id": "D000059350",
                    "term": "Chronic Pain"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010146",
                    "term": "Pain"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000017271",
                    "term": "Craniomandibular Disorders"
                },
                {
                    "id": "D000008336",
                    "term": "Mandibular Diseases"
                },
                {
                    "id": "D000007571",
                    "term": "Jaw Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000007592",
                    "term": "Joint Diseases"
                },
                {
                    "id": "D000009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D000009057",
                    "term": "Stomatognathic Diseases"
                },
                {
                    "id": "D000009209",
                    "term": "Myofascial Pain Syndromes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M29442",
                    "name": "Chronic Pain",
                    "asFound": "Chronic Pain",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16477",
                    "name": "Temporomandibular Joint Disorders",
                    "asFound": "Temporomandibular Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16478",
                    "name": "Temporomandibular Joint Dysfunction Syndrome",
                    "asFound": "Temporomandibular Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M10621",
                    "name": "Joint Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M19566",
                    "name": "Craniomandibular Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11327",
                    "name": "Mandibular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10601",
                    "name": "Jaw Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12017",
                    "name": "Stomatognathic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8486",
                    "name": "Fibromyalgia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12161",
                    "name": "Myofascial Pain Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC07",
                    "name": "Mouth and Tooth Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009270",
                    "term": "Naloxone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009292",
                    "term": "Narcotic Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M12221",
                    "name": "Naloxone",
                    "asFound": "Adapted",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12243",
                    "name": "Narcotic Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                }
            ]
        }
    },
    "hasResults": false
}